More about SBT2055
Test result of SBT2055
Clinical study
Visceral fat decreased
Volunteers (n=101 ; 54 men, 47 women; BMI of 25 to 30 kg/m2 abdominal visceral fat area above 80cm2 20-64 years old) were given 100 g of fermented milk containing SBT2055 (107 cfu/g) or the control for 12 weeks, consumed with a meal.
*SBT2055 consumed as fermented milk. The consumption amountand period were 1 billion cfu/day over 12 weeks.
Source: Takano Y. et al., Japanese Pharmacology & Therapeutics, 41(9), 895-903, (2013)
Weight, subcutaneous fat, and body fat decreased
In addition to subcutaneous fat, body fat, and body weight, visceral fat, BMI, waist, and hip all demonstrated significant decreases.
Volunteers (n=87; 59 men, 28 women; BMI of 24.2 to 30.7 kg/m2 abdominal visceral fat area (81.2–178.5 cm2); 33-63 years old) were given 200g of fermented milk containing SBT2055 (5x108 cfu/g) or the control for 12 weeks, consumed with a meal.
*SBT2055 consumed as fermented milk. The consumption amount and period were 100 billion cfu/day over 12 weeks.
Source: Kadooka Y. et al. European Journal of Clinical Nutrition, 64, 636–643, (2010)
The mechanism of SBT2055 mediated suppression of lipid absorption
Presence of SBT2055 results in reduction in fat droplet size
SBT2055 or a catechin mixture was added to the fat emulsion preparation. The suspension was incubated at 37°C with constant shaking for 3 h and the size distribution of fat emulsion was measured using a particle size analyzer. No sample (only TES buffer) was added to the negative control and the catechin mixture was used as a positive control. Changes in emulsion droplet size distribution after incubation with 1000 μg/ml of SBT2055 or catechin mixture. The distributions are an average of three determinations.
Source: Ogawa A. et al., Lipids in Health and Disease, 14:20, (2015)
Promoted fat excretion
Volunteers (n=30; 12 men, 18 women; 27-69 years old) were given 100 g of fermented milk containing SBT2055 (5x107 cfu/g) or the control for 7 days, consumed with a meal.
*SBT2055 consumed as fermented milk. The consumption amount and period were 5 billion cfu/day over 7 days.
Source: Ogawa A. et al., Lipids in Health and Disease, 14:20, (2015)
Through our studies,
we estimate the mechanism through which SBT2055 reduces fat to be the following.
1. Normal (no SBT2055) digestion and absorption of food-derived fat
- Dietary fat(fat droplet) are emulsified by pancreatic secretions, reducing the size of the fat droplets.
- The smaller fat droplets are broken down by lipase into glycerin and fatty acids, resulting in absorption by the small intestine.
2. Digestion and absorption of Dietary fat when consumed with SBT2055.
- Fat globules consumed through diet are slower to break down when SBT2055 is present.
- The absorption of fat is suppressed due to smaller fat globule size. This is due to lower efficiency of lipase due to smaller surface area per fat weight.
- This results in suppressed fat absorption by the small intestine, causing fat to be excreted outside the body.
Source: Ogawa A. et al., Lipids in Health and Disease, 14:20, (2015)
Safety & Status
- Confirmed via various safety tests
(Specifically, we conducted antibiotic resistance tests, reverse mutation tests, single dose toxicity tests and repeated oral dose toxicity tests, and determined that there were no safety issues.) - Over 20 years of sales performance of products using SBT2055 such as yogurt
- In Japan, yogurt and other products using SBT2055 have been approved as Foods with Function Claims and Foods for Specified Health Uses.
- Isolated from humans
Production
- Product format: Powder
- Strain type: Live bacteria
- Storage conditions: Frozen storage
Application
